Samsung Biologics to Acquire PolyPeptide in $1.81 Billion Cash Deal
Samsung Biologics is set to acquire Swiss-based PolyPeptide Group for SFr1.46 billion ($1.81 billion) through an all-cash public tender offer, aiming to expand its capabilities beyond antibodies and ADCs into the growing peptide therapeutics market.